Literature DB >> 2318251

Type 6 and 19 pneumococcal polysaccharides coupled to erythrocytes elicit pneumococcal cell wall-specific primary IgM responses and capsular polysaccharide-specific secondary IgG responses.

G N Milligan1, R L Fairchild, K E Sterner, H Braley-Mullen.   

Abstract

Previous results have shown that the primary murine antibody responses to vaccine preparations of type 6 (S6; Danish type 6A) or type 19 (S19; Danish type 19F) pneumococcal capsular polysaccharides consist entirely of IgM antipneumococcal cell wall carbohydrate (PnC)-specific antibodies. No capsular polysaccharide-specific IgM antibodies were detectable by plaque-forming cell or enzyme-linked immunosorbent assay techniques. In this report, antibodies specific for S6 and S19 capsular polysaccharides were induced in secondary responses to chicken erythrocyte (CRBC) conjugates of S6 and S19. Essentially all detectable IgG produced in the secondary response was capsular polysaccharide specific and included all subclasses of IgG. In contrast, all detectable IgM produced in the primary response to S6-CRBC and S19-CRBC, and the IgM produced in the secondary response to S6-CRBC was not capsular polysaccharide specific since it reacted with PnC. Thus, there is a major change in the specificity of the primary IgM response compared to the secondary IgG response of mice immunized with S6-CRBC or S19-CRBC. Injection of PnC or any PnC-containing polysaccharide prior to immunization with S6-CRBC or S19-CRBC resulted in suppression of the primary IgM response. In contrast, only the capsular polysaccharide used in the immunizing polysaccharide-erythrocyte conjugate suppressed induction of the capsular polysaccharide-specific secondary IgG response. These results suggest that S6 and S19 capsular polysaccharide-specific IgG-producing memory B cells derive from capsular polysaccharide-specific precursors which do not produce detectable antibody after primary immunization.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318251     DOI: 10.1002/eji.1830200320

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Induction of anti-pneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates.

Authors:  C Peeters; A M Tenbergen-Meekes; J Poolmann; B Zegers; G Rijkers
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

2.  The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Penny Salt; Sarah Oh; Arnaud Marchant; Peter Beverley; Andrew John Pollard
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

3.  Mucosal memory B cells retain the ability to produce IgM antibodies 2 years after oral immunization.

Authors:  M Vajdy; N Lycke
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

4.  Genomic differences among carriage and invasive nontypeable pneumococci circulating in South Africa.

Authors:  Thabo Mohale; Nicole Wolter; Mushal Allam; Susan A Nzenze; Shabir A Madhi; Mignon du Plessis; Anne von Gottberg
Journal:  Microb Genom       Date:  2019-10-11

5.  Genomic analysis of nontypeable pneumococci causing invasive pneumococcal disease in South Africa, 2003-2013.

Authors:  Thabo Mohale; Nicole Wolter; Mushal Allam; Kedibone Ndlangisa; Penny Crowther-Gibson; Mignon du Plessis; Anne von Gottberg
Journal:  BMC Genomics       Date:  2016-06-22       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.